Cargando…
BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
The EGFR and TGFβ signaling pathways are important mediators of tumorigenesis, and cross-talk between them contributes to cancer progression and drug resistance. Therapies capable of simultaneously targeting EGFR and TGFβ could help improve patient outcomes across various cancer types. Here, we deve...
Autores principales: | Boreddy, Srinivas Reddy, Nair, Reshmi, Pandey, Prashant Kumar, Kuriakose, Anshu, Marigowda, Shivakumar Bhadravathi, Dey, Chaitali, Banerjee, Arindam, Kulkarni, Hanumant, Sagar, Milind, Krishn, Shiv Ram, Rao, Shruthi, AR, Madhukara, Tiwari, Vinita, Alke, Bhavna, MV, Prashantha Kumar, Shri, Meena, Dhamne, Chaitrali, Patel, Sonal, Sharma, Pinky, Periyasamy, Sankar, Bhatnagar, Jaya, Kuriakose, Moni Abraham, Reddy, Ram Bhupal, Suresh, Amritha, Sreenivas, Suma, Govindappa, Nagaraja, Moole, Praveen Reddy, Bughani, Usha, Tan, Seng-Lai, Nair, Pradip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236157/ https://www.ncbi.nlm.nih.gov/pubmed/37074042 http://dx.doi.org/10.1158/0008-5472.CAN-21-4425 |
Ejemplares similares
-
Gene and miRNA expression changes in squamous cell carcinoma of larynx and hypopharynx
por: Nair, Jayalakshmi, et al.
Publicado: (2015) -
Molecular prognosticators in clinically and pathologically distinct cohorts of head and neck squamous cell carcinoma—A meta-analysis approach
por: Reddy, Ram Bhupal, et al.
Publicado: (2019) -
Meta-Analyses of Microarray Datasets Identifies ANO1 and FADD as Prognostic Markers of Head and Neck Cancer
por: Reddy, Ram Bhupal, et al.
Publicado: (2016) -
Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
por: Bughani, Usha, et al.
Publicado: (2018) -
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
por: Bughani, Usha, et al.
Publicado: (2017)